Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.58	8.74	12.62	13.16	63.46
Short-Term Investments	52.17	43.22	14.53	29.14	5.99
Cash & Short-Term Investments	56.75	51.96	27.15	42.3	69.45
Cash Growth	9.21%	91.40%	-35.82%	-39.09%	56.92%
Accounts Receivable	0.04	0.08	0.03	0.59	0.51
Other Current Assets	1.43	2.37	0.78	0.77	1.35
Total Current Assets	58.21	54.41	27.96	43.66	71.31
Net Property, Plant & Equipment	1.06	1.33	1.39	2.57	3.64
Long-Term Investments	10.99	12.54	16.12	21.88	34.27
Other Long-Term Assets	0.86	0.63	0.09	0.13	0.24
Total Assets	71.12	68.91	45.55	68.24	109.46
Accounts Payable	2.49	2.58	1.53	1.98	1.57
Accrued Expenses	6.49	3.73	3.97	7.55	7.08
Current Portion of Leases	0.4	0.19	1.37	1.23	1.05
Other Current Liabilities	-	28.91	-	-	-
Total Current Liabilities	9.38	35.4	6.87	10.75	9.69
Long-Term Leases	0.53	0.94	-	1.37	2.6
Total Long-Term Liabilities	0.53	0.94	-	1.37	2.6
Total Liabilities	9.91	36.34	6.87	12.13	12.29
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	474.39	430.86	374.36	364.36	361.67
Accumulated Other Comprehensive Income	-0.9	-1.29	-0.97	-0.56	1.87
Retained Earnings	-412.29	-397.01	-334.72	-307.69	-266.38
Shareholders' Equity	61.21	32.57	38.68	56.12	97.16
Total Liabilities & Equity	71.12	68.91	45.55	68.24	109.46
Total Debt	0.94	1.12	1.37	2.6	3.65
Net Cash (Debt)	55.81	50.84	25.78	39.7	65.8
Net Cash Growth	9.78%	97.25%	-35.08%	-39.67%	56.87%
Net Cash Per Share	0.70	0.83	0.54	0.85	1.57
Book Value	61.21	32.57	38.68	56.12	97.16
Book Value Per Share	0.77	0.53	0.81	1.21	2.32
Tangible Book Value	61.21	32.57	38.68	56.12	97.16
Tangible Book Value Per Share	0.77	0.53	0.81	1.21	2.32

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q